Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.75 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emd-1204831 SCHEMBL2350245 | 0.89 | MET (0.75) | METNQO2 | |
| SCHEMBL3095893 | 0.89 | MET (0.80) | METNQO2 | |
| SCHEMBL3099004 | 0.89 | MET (0.77) | METNQO2 | |
| SCHEMBL2457361 | 0.88 | MET (0.79) | METNQO2 | |
| SCHEMBL12240061 | 0.87 | MET (0.74) | METNQO2 | |
| SCHEMBL2456034 | 0.86 | MET (0.69) | METNQO2 | |
| SCHEMBL2460056 | 0.86 | MET (0.71) | METNQO2 | |
| SCHEMBL3096011 | 0.86 | MET (1.00) | METNQO2 | |
| SCHEMBL3091288 | 0.85 | MET (0.70) | METNQO2 | |
| Emd-1204831 SCHEMBL2346403 | 0.85 | MET (0.70) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | claimed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-8637518-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257181-A1 | PYRIDAZINONE DERIVATIVES | MET, TYRO3, ERBB2 | MET 1/4885NQO2 600/4885MAPT 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.